| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Chen,Jia-Nan | Chairman | 3.86% | |
| Wu,Hong-Ren | Director | 2.33% | |
| CHANG SHYANG ENTERPRISE CO., LTD. | Director | 3.63% | |
| Huang,Zhong-Yang | Director | 2.45% | |
| Ceng,Tian-Ci | Director | 1.01% | |
| Qiu,Xiu-Zhen | Independent Director | 0.00% | |
| Chen,Zhong-Xi | Independent Director | 0.40% | |
| Zheng,Hong-Hui | Independent Director | 0.00% | |
| Xia,Shang-Pu | Independent Director | 0.00% |
Change Company Name to Great Novel Therapeutics Biotech & Medicals Corporation
2024/07/05
Change Company Name to HUASHANG BIOTECH PHARMACEUTICAL CO., LTD. (FORMER NAME: HUASHANG BIOTECH CO., LTD.)
2022/10/18
Change Capital to 600,000,000
2022/06/30
Change Person in Charge to Chen,Jia-Nan
2016/04/28
Change Company Name to Great Novel Therapeutics Biotech & Medicals Corporation
2013/10/15
Change Capital to 300,000,000
2013/10/15
Change Person in Charge to Tang,Shang-Wen
2013/10/15
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 527 | 4,850 | 540 |
| Operating cost | 200 | 43 | 76 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 327 | 4,807 | 464 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 327 | 4,807 | 464 |
| Operating expenses | 65,390 | 70,627 | 69,255 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -65,063 | -65,820 | -68,791 |
| Non-operating income and expenses | 3,104 | 4,823 | 1,659 |
| Net profit (loss) before tax | -61,959 | -60,997 | -67,132 |
| Income tax expense (benefits) | - | - | - |
| Net profit (loss) of ongoing business for the current period | -61,959 | -60,997 | -67,132 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -61,959 | -60,997 | -67,132 |
| Other comprehensive profit (loss), net | - | - | - |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -61,959 | -60,997 | -67,132 |
| Net profit (loss) attributable to owners of parent company | - | - | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | - | - | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | -1 | -1 | -2 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | - | - | - |
| Net cash inflows (outflows) from investing activities | - | - | - |
| Net cash inflow (outflow) from financing activities | - | - | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | - | - | - |
| Beginning balance of cash and cash equivalents | - | - | - |
| Ending balance of cash and cash equivalents | - | - | - |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 627,402 | 485,454 | 251,454 |
| Non-current asset | 73,361 | 75,796 | 37,251 |
| Total asset | 700,763 | 561,250 | 288,705 |
| Current liability | 20,971 | 15,932 | 12,047 |
| Non-current liability | 8,909 | 10,881 | - |
| Total liability | 29,880 | 26,813 | 12,047 |
| share capital | 434,870 | 383,575 | 292,865 |
| Equity - secruity token | - | - | - |
| capital reserve | 738,227 | 591,117 | 363,051 |
| retained earning | -502,214 | -440,255 | -379,258 |
| Other equity | - | - | - |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | - | - | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 670,883 | 534,437 | 276,658 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 15 | 13 | 9 |
